fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Mutual Funds » Nippon India PHARMA Fund

Nippon India PHARMA Fund - G

NAV  ₹349.301 ↑ 0.24  (0.07 %) as on 22 Aug 23

Scheme Objective

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

Nippon India Pharma Fund is a Equity - Sectoral fund launched on 5 Jun 04. It is a fund with High risk and has given a CAGR return of 20.3% since its launch.  Ranked 35 in Sectoral category.  Return for 2022 was -9.9% , 2021 was 23.9% and 2020 was 66.4% .

Below is the key information for Nippon India Pharma Fund

NAV as on 22 Aug 23₹349.301 ↑ 0.24  (0.07 %)
Net Assets (AUM) as on 31 Jul 2023 ₹5,392 Cr.
Launch Date5 Jun 2004
CategoryEquity - Sectoral
Rating
TypeOpen Ended Fund
RiskHigh
AMCNippon Life Asset Management Ltd.
Alpha Ratio2.26
Expense Ratio1.97 %
Sharpe Ratio1.198
Information Ratio0.62
BenchmarkNot Available
Min Investment ₹5,000
Min SIP Investment ₹100
Exit Load 0-1 Years (1%),1 Years and above(NIL)

Returns

Annual Compounded Returns

Returns up to 1 year are on absolute basis & more than 1 year are on CAGR (Compound Annual Growth Rate) basis. as on 22 Aug 23

DurationReturns
1 Month 5.6%
3 Month 24.7%
6 Month 29.2%
1 Year 27.3%
3 Year 16.2%
5 Year 17.5%
10 Year
15 Year
Since launch 20.3%

Historical Annual Returns

Historical performance (Yearly) on absolute basis

YearReturns
2022 -9.9%
2021 23.9%
2020 66.4%
2019 1.7%
2018 3.6%
2017 7.6%
2016 -10.6%
2015 19.4%
2014 49.5%

Growth of 10k Over Years

DateValue
31 Aug 18₹10,000
31 Aug 19₹8,733
31 Aug 20₹13,180
31 Aug 21₹19,501
31 Aug 22₹17,099
31 Aug 23₹21,433
Nippon India PHARMA Fund Growth 10k Chart

Asset Allocation

Asset ClassValue
Cash3.22%
Equity96.78%
Nippon India PHARMA Fund Asset Allocation

Sector Allocation

SectorValue
Health Care96.78%
Nippon India PHARMA Fund Equity Allocation

Top Securities Holdings / Portfolio

Holdings/Securities

NameGlobal IndustryHoldingValueQuantity
Sun Pharmaceuticals Industries Ltd (Healthcare)
Equity, Since 31 Oct 09 | SUNPHARMA
Drug Manufacturers - Specialty & Generic13%₹729 Cr6,556,349
Lupin Ltd (Healthcare)
Equity, Since 31 Aug 08 | 500257
Drug Manufacturers - Specialty & Generic8%₹418 Cr3,803,676
↓ -200,000
Cipla Ltd Shs Dematerialised (Healthcare)
Equity, Since 31 May 08 | 500087
Drug Manufacturers - General7%₹377 Cr3,000,000
Dr Reddy's Laboratories Ltd (Healthcare)
Equity, Since 30 Jun 11 | DRREDDY
Drug Manufacturers - Specialty & Generic6%₹308 Cr550,030
Gland Pharma Ltd (Healthcare)
Equity, Since 30 Nov 20 | GLAND
Drug Manufacturers - General5%₹261 Cr1,500,000
↑ 300,000
Divi's Laboratories Ltd (Healthcare)
Equity, Since 31 Mar 12 | DIVISLAB
Drug Manufacturers - Specialty & Generic5%₹252 Cr700,808
Medplus Health Services Ltd (Healthcare)
Equity, Since 30 Nov 22 | 543427
Pharmaceutical Retailers5%₹250 Cr3,076,603
↑ 1,160,000
Aurobindo Pharma Ltd (Healthcare)
Equity, Since 31 Dec 15 | AUROPHARMA
Drug Manufacturers - Specialty & Generic4%₹208 Cr2,500,000
↓ -500,000
J.B. Chemicals & Pharmaceuticals Ltd Shs Dematerialised (Healthcare)
Equity, Since 31 Jan 22 | JBCHEPHARM
Drug Manufacturers - Specialty & Generic4%₹207 Cr748,446
↓ -10,132
Zydus Lifesciences Ltd (Healthcare)
Equity, Since 31 Jan 18 | 532321
Drug Manufacturers - Specialty & Generic4%₹200 Cr3,200,835
1 - 10 of 33
Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Fund Managers

NameSinceTenure
Sailesh Raj Bhan1 Apr 0518.43 Yr.
Kinjal Desai25 May 185.27 Yr.
Akshay Sharma1 Dec 220.75 Yr.

Custodians

CompanyAddress
Deutsche Bank AGDeutsche Bank AG,Kodak House, 22, D.N. Road,

Registrar & Transfer Agent

KFin Technologies Ltd
AddressKFin Technologies Pvt. Ltd,,1D/D Extension 2, Valmiki Chowk,,Gandhi Nagar,
FAX91-40-23311968
Emailmailmanager@karvy.com

Administrator Companies

CompanyAddress
Nippon India Mutual Fund9th Floor, Crescenzo, C-38 & 39,,G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400051

Auditors

CompanyAddress
Haribhakti & Co. Chartered Accountants42, Free Press House,4th Floor,,215, Nariman Point,

All Plan & Options

Fund and PlanNAV6 Month1 Year3 Year5 Year
Nippon India Pharma Fund
Normal Dividend, Payout
₹96.9949
↑ 0.07
29.22 %27.26 %20.83 %19.83 %
Nippon India Pharma Fund
Normal Dividend, Reinvestment
₹96.9949
↑ 0.07
29.22 %27.26 %20.83 %19.83 %
Nippon India Pharma Fund
Growth
₹349.301
↑ 0.24
29.22 %27.26 %16.16 %17.49 %
Data as on 22 Aug 23

Disclaimer:
All efforts have been made to ensure the information provided here is accurate. However, no guarantees are made regarding correctness of data.